Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Infliximab (Remsima®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2254. 2015 Authors' conclusions Infliximab (Remsima®) is recommended as an option for restricted use within NHS Wales. Infliximab (Remsima® should be prescribed within its licensed indications in accordance with NICE or AWMSG guidance for infliximab (Remicade®), the reference product. Infliximab (Remsima®)should be prescribed by brand name to avoid automatic substitution and therefore help with pharmacovigilance. Indexing Status Subject indexing assigned by CRD MeSH Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Humans Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Email: AWTTC@wales.nhs.uk AccessionNumber 32015000592 Date abstract record published 01/06/2015 |